3,4-二氢-2H-1,5-苯并二氧-7-羧酸 | 20825-89-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,4-二氢-2H-1,5-苯并二氧-7-羧酸
• 中文别名: 3,4-二氢-2H-1,5-苯并二氧杂卓-7-羧酸；3,4-二氢-2H-1,5-苯并二氧杂卓-8-羧酸
• 英文名称: 3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid
• 英文别名: 3,4-dihydro-2H-1,5-benzodioxepine-7-carboxylic acid；3,4-dihydro-2H-1,5-benzodioxepin-7-carboxylic acid
• CAS: 20825-89-2
• 化学式: C₁₀H₁₀O₄
• mdl: MFCD00276310
• 分子量: 194.187
• InChiKey: MQSSBVLREFSMDP-UHFFFAOYSA-N

物化性质

• 熔点：
  145-147°C
• 沸点：
  351.0±31.0 °C(Predicted)
• 密度：
  1.306±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2932999099

SDS

Name:	3 4-Dihydro-2H-1 5-benzodioxepine-7-carboxylic acid 97% Material Safety Data Sheet
Synonym:
CAS:	20825-89-2

Section 1 - Chemical Product MSDS Name:3 4-Dihydro-2H-1 5-benzodioxepine-7-carboxylic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20825-89-2	3,4-Dihydro-2H-1,5-benzodioxepine-7-ca	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20825-89-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 145.2 - 147.3 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10O4
Molecular Weight: 194

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20825-89-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3,4-Dihydro-2H-1,5-benzodioxepine-7-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 20825-89-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20825-89-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20825-89-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-1,5-苯并二氧-7-羧酸 在 五氯化磷 作用下， 以 环己烷 为溶剂， 生成 3,4-二氢-2H-1,5-苯并二氧-7-羰酰氯
  参考文献：
  名称：

  作为具有 FabH 抑制活性的有效抗菌剂的双氧化酰胺衍生物的靶点鉴定和优化

  摘要：

  FabH 酶在脂肪酸生物合成的第一步中起着至关重要的作用，这对细菌的生存至关重要。因此，FabH 已成为开发新型抗菌剂的一个有吸引力的目标。在这项研究中，我们采用化学蛋白质组学方法，验证了先前鉴定的带有双氧环的骨架酰胺衍生物，这些衍生物可能是通过代谢过程形成的。基于蛋白质组学研究结果，我们合成并评估了 32 种含有N-杂环酰胺的化合物的抗菌活性，以便将来优化脱氧酰胺。几种化合物表现出有效的低毒性抗菌特性，特别是化合物25 ，它作为一种药物表现出巨大的潜力，对测试的细菌菌株的 MIC 范围为 1.25–3.13 μg/mL，对大肠杆菌衍生的IC 50为 2.0 μM法布H。此外，我们通过细胞毒性和溶血活性评估、Lipinski 的五规则标准以及计算机 ADMET 预测来评估 9 种具有相对较低 MIC 值的类似物，以确定其成药潜力。值得注意的是，进行了详细的对接模拟以研究化合物25在大肠杆菌FabH

  DOI：

  10.1016/j.ejmech.2023.116064
• 作为产物：
  描述：

  3,4-二氢-2H-1,5-苯并二噁平-7-甲醛 在 potassium permanganate 作用下， 以 水 为溶剂， 反应 5.0h， 以73%的产率得到3,4-二氢-2H-1,5-苯并二氧-7-羧酸
  参考文献：
  名称：

  作为潜在 β-酮酰基-酰基载体蛋白合酶 III (FabH) 抑制剂的新型酰胺衍生物的设计、合成和抗菌活性

  摘要：

  脂肪酸的生物合成对细菌的生存至关重要。在这些有希望的靶点中，β-酮酰基-酰基载体蛋白 (ACP) 合酶 III (FabH) 是最有吸引力的靶点。FabH 将触发脂肪酸生物合成的启动，并且在革兰氏阳性和阴性细菌中高度保守。合成并开发了一系列带有双氧合环的新型酰胺衍生物，作为 FabH 的有效抑制剂。这些化合物通过1 H-NMR、13 C-NMR、MS 测定，并通过化合物19的晶体衍射研究进一步证实。此外，这些化合物被评估为强广谱抗菌活性。对一些具有强效抗菌活性的化合物进行了大肠杆菌检测(大肠杆菌) FabH 抑制活性。特别是，化合物19显示出最有效的抗菌活性，对测试菌株的最小抑制浓度 (MIC) 值为 1.56-3.13 mg/mL，并显示出最有效的大肠杆菌FabH 抑制活性，IC 50为 2.4 µM。进行对接模拟以将化合物19定位到大肠杆菌FabH 活性位点以确定可能的结合构象。 全尺寸图像

  DOI：

  10.1248/cpb.c22-00090

文献信息

• [EN] FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRODIOXINE FUSIONNÉS À UTILISER EN TANT QU'INHIBITEURS DE FACTEUR DE TRANSCRIPTION 1 DU CHOC THERMIQUE
  申请人：CANCER REC TECH LTD

  公开号：WO2015049535A1

  公开（公告）日：2015-04-09

  The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式I的化合物，其中A1、A2、R4和Q如本文所定义。本发明的化合物是热休克因子1（HSF1）的抑制剂。具体来说，本发明涉及将这些化合物用作治疗和/或预防增殖性疾病，如癌症的治疗剂。本发明还涉及制备这些化合物的方法，以及包含它们的药物组合物。
• Structure-Based Optimization of Pyridoxal 5′-Phosphate-Dependent Transaminase Enzyme (BioA) Inhibitors that Target Biotin Biosynthesis in <i>Mycobacterium tuberculosis</i>
  作者：Feng Liu、Surendra Dawadi、Kimberly M. Maize、Ran Dai、Sae Woong Park、Dirk Schnappinger、Barry C. Finzel、Courtney C. Aldrich

  DOI：10.1021/acs.jmedchem.7b00189

  日期：2017.7.13

  relationships (SAR) through the design, synthesis, and biological evaluation of a systematic series of analogues of the original hit using a structure-based drug design strategy, which was enabled by cocrystallization of several analogues with BioA. To confirm target engagement and discern analogues with off-target activity, each compound was evaluated against wild-type (WT) Mtb in biotin-free and -containing

  吡咯醛5'-磷酸（PLP）依赖性转氨酶BioA催化结核分枝杆菌（Mtb）中生物素生物合成的第二步，并且是细菌存活和体内持久性所必需的酶。含有N-芳基，N的有前途的BioA抑制剂6以前已通过基于靶标的全细胞筛选确定了'-苯甲酰基哌嗪支架。在这里，我们使用基于结构的药物设计策略，通过设计，合成和生物学评估原始命中的系统类似物系列，探索结构与活性之间的关系（SAR），该策略是通过将几种类似物与BioA共结晶而实现的。为了确认靶标参与并辨别具有脱靶活性的类似物，评估了每种化合物在无生物素和含培养基的培养基中以及在表达过少和过表达的BioA Mtb菌株中对野生型（WT）Mtb的能力。构象受限的导数36成为最强的K D类似物为76nm针对的bioA和1.7μM（0.6微克/毫升）对的最小抑制浓度的Mtb在无生物素培养基。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20030144175A1

  公开（公告）日：2003-07-31

  The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了4-氨基-氮杂七环-3-酮蛋白酶抑制剂及其药用可接受的盐、水合物和溶剂化物，其抑制蛋白酶，包括卡特普辛K，这些化合物的药物组合物，这些化合物的新中间体，以及治疗骨骼过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说，是骨关节炎和类风湿关节炎；帕吉特病；恶性高钙血症；和代谢性骨病，包括通过向需要的患者施用本发明化合物来抑制骨质流失或过度软骨或基质降解。
• Bicyclic pyrazole compounds as antibacterial agents
  申请人：Allison D. Brett

  公开号：US20060223810A1

  公开（公告）日：2006-10-05

  Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.

  抗菌化合物、含有它们的组合物以及用于抑制细菌活性以及治疗、预防或抑制细菌感染的方法。
• [EN] SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS<br/>[FR] ACTIVATEURS À PETITES MOLÉCULES D'ALDOLASE-TRAP DE LA MALARIA ET INHIBITEURS DU GLIDÉOSOME
  申请人：UNIV NEW YORK

  公开号：WO2013063243A1

  公开（公告）日：2013-05-02

  In one aspect, the present invention relates to a method of identifying compounds useful in modifying the activity of Aldolase. The method includes providing a first model comprising Aldolase or residues of the amino acid sequence corresponding to SEQ ID NO: 1 said residues being at amino acid positions selected from the group consisting of 10-13, 26, 27, 29, 30, 31, 32, 33, 37, 39, 40, 41, 43, 44, 47, 48, 51, 52, 60, 63, 66, 79, 84, 85, 92, 93, 103, 106-109, 112-117, 138, 142, 146, 148, 151, 153, 179, 182, 183, 185, 186, 194, 196, 197, 198, 199, 208, 226-228, 231- 269, 270, 272, 277-283, 285-289, 294, 295, 297-299, 301-304, 306-310, 312, 313, 316, 317, 319, 321, 323, 326, 330, 344, 345, and 347, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for modifying the activity of Aldolase. The present invention also discloses compounds and compositions which modify the activity of Aldolase, or a complex between Aldolase and TRAP. Methods of treating or preventing malaria, or an infection by apicomplexan organisms are also disclosed.

  在一个方面，本发明涉及一种识别有助于修改Aldolase活性的化合物的方法。该方法包括提供一个第一模型，该模型包括Aldolase或者与SEQ ID NO: 1相对应的氨基酸序列残基，所述残基位于氨基酸位置中的一个或多个位置，所选位置包括10-13、26、27、29、30、31、32、33、37、39、40、41、43、44、47、48、51、52、60、63、66、79、84、85、92、93、103、106-109、112-117、138、142、146、148、151、153、179、182、183、185、186、194、196、197、198、199、208、226-228、231-269、270、272、277-283、285-289、294、295、297-299、301-304、306-310、312、313、316、317、319、321、323、326、330、344、345和347，提供一个或多个候选化合物，评估候选化合物与第一模型之间的接触，以确定哪些候选化合物具有结合和/或适配第一模型的能力，并识别化合物，这些化合物根据所述评估具有结合和/或适配第一模型的能力，可能有助于修改Aldolase活性。本发明还公开了修改Aldolase活性的化合物和组合物，或者Aldolase和TRAP之间的复合物。还公开了治疗或预防疟疾或被顶复门原生生物感染的方法。